



# Polyplex Corporation Limited

## Margin to moderate; downgrade to Hold

Plastic & Packaging

Sharekhan code: POLYPLEX

Result Update

### 3R MATRIX

	+	=	-
Right Sector (RS)	Green	Grey with check	Red
Right Quality (RQ)	Green with check	Grey	Red
Right Valuation (RV)	Green	Grey with check	Red

+ Positive = Neutral - Negative

### What has changed in 3R MATRIX

	Old		New
RS	Grey	↔	Grey
RQ	Green	↔	Green
RV	Green	↓	Grey

### Reco/View

Reco: <b>Hold</b>	Change ↓
CMP: <b>Rs. 918</b>	
Price Target: <b>Rs. 950</b>	Change ↑

↑ Upgrade ↔ Maintain ↓ Downgrade


### Company details

Market cap:	Rs. 2,882 cr
52-week high/low:	Rs. 945/283
NSE volume: (No of shares)	1.5 lakh
BSE code:	524051
NSE code:	POLYPLEX
Free float: (No of shares)	1.5 cr

### Shareholding (%)

Promoters	51.0
FII	7.5
DII	6.1
Others	35.4

### Price chart



### Price performance

(%)	1m	3m	6m	12m
Absolute	28.3	22.6	22.5	70.5
Relative to Sensex	24.2	3.8	-11.8	46.5

Sharekhan Research, Bloomberg

### Summary

- Post a sharp increase in PCL's stock price, valuation of 6.3x FY2023E EPS is above its 5-year average one-year forward PE multiple of 5.2x and limits further valuation re-rating given cyclical nature of the business. Hence, we downgrade PCL to Hold (from Buy) with a revised PT of Rs.950.
- Q3FY21 consolidated adjusted operating profit at Rs. 329 crore (up 54.6% y-o-y; up 1.6% q-o-q) slightly lagged estimates as beat in volumes (up 19.6% y-o-y) was offset by a miss in OPM by 89 bps to 26.6%.
- BOPET spreads seem to have peaked out and could contract going forward as realisations fall with a rise in supplies, while raw material costs also harden as oil prices surge to \$61/bbl.
- We believe that PCL's FY2021E margin/PAT of 26.7%/Rs. 516 crore are near peaks of the BOPET margin cycle and are not sustainable over FY2022E-FY2023E despite addition of new capacities (capex plan of \$195 million).

Polyplex Corporation Limited's (PCL) Q3FY2021 consolidated revenues increased by 13.3% y-o-y (largely flat q-o-q) to Rs. 1,237 crore, in-line with our estimates of Rs. 1,266 crore. Strong revenue growth was driven by sharp 19.6% y-o-y increase in volume to 80,283 mt but the same was partially offset by a 5.2% y-o-y decline in blended realisation. Adjusted operating profit at Rs.329 crore (up 54.6% y-o-y; up 4.6% q-o-q) was 2% below our estimate of Rs. 337 crore due to miss of 89 bps in OPM at 26.6% (up 710 bps; up 20 bps q-o-q). Gross margin remained strong at 53.1% (up 687 bps y-o-y; up 228 bps q-o-q) although slightly lower than our estimate of 53.6%. The value-added-spreads remained largely stable q-o-q at \$1.04/kg. Adjusted PAT before minority interest at Rs. 269 crore (up 81.4% y-o-y; flat q-o-q) was marginally above estimate of Rs. 221 crore due to higher other income and lower depreciation which offset slight in miss in OPM. However, adjusted PAT after minority interest at Rs. 131 crore (up 57.2% y-o-y; up 43.8% q-o-q) was significantly below our estimate of Rs.171 crore. In our view, BOPET spreads have peaked out and expected to contract from hereon given addition of new lines globally (one line recently commissioned in Nigeria) and likely increase in raw material cost (as oil price recovered sharply to \$61/bbl). We thus believe that PCL's FY2021E EBITDA margin/PAT of 26.7%/Rs.516 crore are near peak level of BOPET margin cycle and not sustainable over FY2022E-FY2023E despite addition of new capacities (capex plan of \$195 million). Also, PCL's valuation of 6.3x FY2023E EPS is above its 5-year average one-year forward PE multiple of 5.2x and limits further valuation re-rating given cyclical nature of the business. Hence, we downgrade PCL to Hold (from Buy) with a revised PT of Rs. 950.

### Key positives

- Better-than-expected volume growth of 19.5% y-o-y to 80,283 mt versus expectation of 10% y-o-y volume growth.
- Special dividend of Rs.100/share takes total dividend to Rs.147/share (implies 16% dividend yield) for FY2021.

### Key negatives

- Lower-than-expected OPM at 26.6% versus expectation of 27.5%.

### Our Call

**Valuation – Downgrade PCL to Hold with revised PT of Rs. 950:** PCL stock price has rallied sharply by 71% in the last one year led by strong earnings performance supported by ramp-up of volumes and high EBITDA margins. Moreover, the management's focus to reward shareholders through dividends [Rs. 147/share for FY2021 (16% dividend yield) including special dividend of Rs.100/share] has been taken positively by the investors. We believe that PCL's earnings momentum would taper off over FY2022-FY2023 despite addition of new capacities (post expectation of record PAT of Rs.516 crore in FY2021E) as BOPET spreads seems to be peaked out and likely to contract with higher supplies from addition of BOPET lines globally. Moreover, PCL's valuation of 6.3x FY2023E EPS is above its 5-year average one year forward PE multiple of 5.2x and limits further valuation re-rating given cyclical nature of the business. Hence, we downgrade PCL to Hold (from Buy) with a revised PT of Rs. 950.

### Key risk

Lower capacity addition globally could result into higher BOPET film margin and better-than-expected demand could result in higher volume growth.

### Valuation (Consolidated)

Particulars	Rs cr				
	FY19	FY20	FY21E	FY22E	FY23E
Revenues	4,570	4,487	4,966	4,991	5,608
OPM (%)	16.0	17.4	26.7	23.6	22.7
Adjusted PAT	330	282	516	437	475
% YoY growth	107.0	-14.5	82.8	-15.3	8.7
Adjusted EPS	101.4	86.6	158.4	134.2	145.8
P/E (x)	9.1	10.6	5.8	6.8	6.3
P/B (x)	1.1	1.0	0.9	0.8	0.7
EV/EBITDA (x)	3.9	3.4	1.8	1.9	1.6
RoNW (%)	12.4	9.7	16.1	12.5	12.5
RoCE (%)	15.2	11.9	19.7	15.0	14.9

Source: Company; Sharekhan estimates

**Broadly in-line performance as higher-than-expected volume growth gets off by miss in OPM:** Q3FY2021 consolidated revenues increased by 13.3% y-o-y (largely flat q-o-q) to Rs. 1,237 crore, in-line with our estimates of Rs. 1,266 crore. Strong revenue growth was driven by sharp 19.6% y-o-y increase in volume to 80,283 mt but the same was partially offset by a 5.2% y-o-y decline in blended realisation. Operating profit at Rs.329 crore (up 54.6% y-o-y; up 4.6% q-o-q) was 2% below our estimate of Rs. 337 crore due to miss of 89 bps in OPM at 26.6% (up 710 bps; up 20 bps q-o-q). Gross margin remained strong at 53.1% (up 687 bps y-o-y; up 228 bps q-o-q) although slightly lower than our estimate of 53.6%. The value-added-spreads remained largely stable q-o-q at \$1.04/kg. Adjusted PAT before minority interest at Rs. 269 crore (up 81.4% y-o-y; flat q-o-q) was marginally above estimate of Rs. 221 crore due to higher other income and lower depreciation which offset slight miss in OPM. However, adjusted PAT after minority interest at Rs. 131 crore (up 57.2% y-o-y; up 43.8% q-o-q) was significantly below our estimate of Rs.171 crore.

**Capex to expand BOPP and BOPET lines – to drive volume growth in FY2023:** The recently-commissioned BOPET line at Indonesia has been fully ramped and is driving volume growth in current fiscal. Further, the company is setting up 60 ktpa BOPP line in Indonesia (\$53 million capex and scheduled to be commissioned in H1FY2022), 50-ktpa BOPET line in the US (\$83 million capex and to be commissioned by H2FY2023). Overall capex plan is at \$195 million over FY2021E-FY2023E for expansion of the BOPP and BOPET lines, which would drive sustained volume growth over the next few years.

#### Capex schedule over FY2022-FY2023

Projects	Location	Capital cost (\$ million)	Likely Start Up
Brownfield - BOPP	Indonesia	53	H1FY2022
Brownfield - BOPET	USA	83	H2FY2023
Other Projects	India	3	Upto Q3FY2022
Other Projects	Overseas	56	Upto Q4FY2022
<b>Total</b>		<b>195</b>	

Source: Company; Sharekhan Research

#### Results (consolidated)

Particulars	Rs cr				
	Q3FY21	Q3FY20	YoY (%)	Q2FY21	QoQ (%)
<b>Net Sales</b>	<b>1,237</b>	<b>1,092</b>	<b>13.3</b>	<b>1,227</b>	<b>0.8</b>
Total Expenditure	908	879	3.3	1,047	-13.3
<b>Operating profit</b>	<b>329</b>	<b>213</b>	<b>54.6</b>	<b>181</b>	<b>82.4</b>
<b>Adjusted operating profit</b>	<b>329</b>	<b>213</b>	<b>54.6</b>	<b>324</b>	<b>1.6</b>
Other Income	14	3	407.2	13	11.1
Interest	4	4	-2.3	4	-7.4
Depreciation	71	61	16.5	69	1.9
Exceptional income/(expense)	<b>0</b>	<b>0</b>	NA	<b>0</b>	NA
<b>Reported PBT</b>	<b>269</b>	<b>151</b>	<b>77.9</b>	<b>120</b>	<b>124.7</b>
<b>Adjusted PBT</b>	<b>269</b>	<b>151</b>	<b>77.9</b>	<b>263</b>	<b>2.1</b>
Tax	44	27	61.9	17	153.5
RPAT before minority interest	225	124	81.4	102	119.8
Adjusted PAT before minority interest	225	124	81.4	225	-0.1
Minority interest	93	53	76.5	26	262.6
<b>RPAT after minority interest</b>	<b>131</b>	<b>71</b>	<b>85.0</b>	<b>77</b>	<b>71.7</b>
<b>Adjusted PAT after minority interest</b>	<b>131</b>	<b>71</b>	<b>85.0</b>	<b>168</b>	<b>-22.0</b>
Equity Cap (cr)	3	3		3	
Reported EPS (Rs.)	41.1	22.2	85.0	23.9	71.7
Adjusted EPS	41.1	22.2	85.0	52.6	-22.0
<b>Margins (%)</b>			<b>BPS</b>		<b>BPS</b>
OPM	26.6	19.5	710	26.4	20
Effective tax rate	16.4	18.0	-162	14.5	186
<b>NPM</b>	<b>10.6</b>	<b>6.5</b>	<b>411</b>	<b>13.7</b>	<b>-310</b>

Source: Company; Sharekhan Research

## Outlook and Valuation

### ■ Sector View – BOPET demand to remain strong but margins to decline as new capacities come onstream

The flexible packaging segment has witnessed strong demand traction from the consumer staples, food and health & hygiene segments, which in turn is expected drive volumes for producers of BOPET films in the near to medium term. Overall, BOPET demand is expected to grow at a healthy rate of 7-8% over the next few years. However, we believe that BOPET margin have peaked out and expected to moderate as new BOPET lines are expected to come on-stream and thus we expect margins to decline over FY2022-F2023.


### ■ Company Outlook – Profitability at peak; earnings to moderate over FY2022E-FY2023E

Volume growth is likely to remain strong, supported by its recent BOPET capacity expansion by 16% to 312,645 tonnes (recent commissioning of BOPET capacity of 44,000 MT in Indonesia). The company is also expanding its BOPP capacity by 19% and the same is expected to get completed in H1FY2022. Hence, we believe capacity expansion would drive a 9% volume CAGR for PCL over FY2020-FY2023E. However, EBITDA margins are expected to contract by 401 bps over FY2021-FY2023 as BOPET spread expected to contract going forward.

### ■ Valuation – Downgrade PCL to Hold with revised PT of Rs. 950

PCL stock price has rallied sharply by 71% in the last one year led by strong earnings performance supported by ramp-up of volumes and high EBITDA margins. Moreover, the management's focus to reward shareholders through dividends [Rs. 147/share for FY2021 (16% dividend yield) including special dividend of Rs.100/share] has been taken positively by the investors. We believe that PCL's earnings momentum would taper off over FY2022-FY2023 despite addition of new capacities (post expectation of record PAT of Rs.516 crore in FY2021E) as BOPET spreads seems to be peaked out and likely to contract with higher supplies from addition of BOPET lines globally. Moreover, PCL's valuation of 6.3x FY2023E EPS is above its 5-year average one year forward PE multiple of 5.2x and limits further valuation re-rating given cyclical natural of the business. Hence, we downgrade PCL to Hold (from Buy) with a revised PT of Rs. 950.

#### One-year forward P/E (x) band



Source: Sharekhan Research

## About company

PCL is among the largest BOPET film company globally in terms of capacities. The company's polyester capabilities include both PET thin film (230,000 tonne) and PET thick films (28,800 tonne) and its business portfolio includes BOPP, Blown PP/PE, and CPP films. The company has manufacturing units in India (90,000 tonne – 29% of capacity), Thailand (89,645 tonne – 29% of capacity), Turkey (58,000 tonne – 19% of capacity), US (31,000 tonne – 10% of capacity), and Indonesia (44,000 tonne – 14% of capacity).

## Investment theme

Robust demand for packaging and capacity additions by PCL in the BOPET segment would aid volume growth. However, we believe that BOPET margin cycle is near peak levels and spreads are expected to contract from current level with rise in supplies are higher raw material cost. Hence, we believe that PCL's profitability has also peak out and not sustainable as margin would decline over FY2022E-FY2023E.

## Key Risks

- ◆ Lower BOPET capacity addition globally could result into higher BOPET film margin.
- ◆ Better-than-expected demand could result higher volume growth for PCL and vice versa.

## Additional Data

### Key management personnel

Sanjiv Saraf	Chairman
Pranay Kothari	Chief Executive Officer
Manish Gupta	Chief Financial Officer

Source: Company Website

### Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	Reliance Capital Trustee Co Ltd	4.6
2	KESWANI HARESH TIKAMDAS	3.2
3	Haresh Keswani	3.0
4	BHANSHALI AKASH	1.7
5	Finquest Securities Pvt Ltd	1.3
6	Soyuz Trading Co Ltd	1.3
7	IL&FS Trust Co Ltd	1.2
8	Kirpalani Ricky Ishwardas	1.1
9	WisdomTree Investments Inc	1.0
10	Dimensional Fund Advisors LP	0.9

Source: Bloomberg; Note: Shareholding as on November 13, 2020

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

## Understanding the Sharekhan 3R Matrix

Right Sector	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
Right Quality	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/weak realisation environment resulting in margin pressure and deteriorating balance sheet
Right Valuation	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research

# Sharekhan

by BNP PARIBAS

Know more about our products and services

For Private Circulation only

**Disclaimer:** This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst further certifies that neither he or its associates or his relatives has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: [compliance@sharekhan.com](mailto:compliance@sharekhan.com);

For any queries or grievances kindly email [igc@sharekhan.com](mailto:igc@sharekhan.com) or contact: [myaccount@sharekhan.com](mailto:myaccount@sharekhan.com)

**Registered Office:** Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on [www.sharekhan.com](http://www.sharekhan.com); Investment in securities market are subject to market risks, read all the related documents carefully before investing.